Maxcyte, Inc. (MXCT)
Nasdaq · Services-Commercial Physical & Biological Research · Services · CIK 1287098 · fiscal year ends in Dec
Closing price $1.58 on 30 Oct 2026; 52-week range $0.68 to $1.76.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $31.1M
- Revenue growth
- -13.2%
- Net income, last twelve months
- -$35.6M
- Earnings per share
- -$0.33
- Gross margin
- 79.2%
- Operating margin
- -134.6%
- Net margin
- -114.8%
- Free cash flow
- -$23.6M
- Return on equity
- -22.4%
- Market value
- $168.2M
- Cash
- $15.0M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 106.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $33.0M | -$51.9M | -$44.6M | -$0.42 | -$36.2M | 10-K filed 25 Mar 2026 |
| FY2024 | 31 Dec 2024 | $38.6M | -$51.2M | -$41.1M | -$0.39 | -$29.3M | 10-K filed 11 Mar 2025 |
| FY2023 | 31 Dec 2023 | $41.3M | -$48.3M | -$37.9M | -$0.37 | -$25.4M | 10-K filed 12 Mar 2024 |
| FY2022 | 31 Dec 2022 | $44.3M | -$27.4M | -$23.6M | -$0.23 | -$33.3M | 10-K filed 15 Mar 2023 |
| FY2021 | 31 Dec 2021 | $33.9M | -$18.2M | -$19.1M | -$0.21 | -$14.5M | 10-K filed 22 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $7.3M | -$8.9M | -$0.08 |
| Q1 FY2026 | 31 Mar 2026 | $9.7M | -$4.8M | -$0.04 |
| Q4 FY2025 | 31 Dec 2025 | $7.3M | -$9.6M | -$0.09 |
| Q3 FY2025 | 30 Sep 2025 | $6.8M | -$12.4M | -$0.12 |
| Q2 FY2025 | 30 Jun 2025 | $8.5M | -$12.4M | -$0.12 |
| Q1 FY2025 | 31 Mar 2025 | $10.4M | -$10.3M | -$0.10 |
| Q4 FY2024 | 31 Dec 2024 | $8.7M | -$10.6M | -$0.10 |
| Q3 FY2024 | 30 Sep 2024 | $8.2M | -$11.6M | -$0.11 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product sales | $18.7M | 56.6% |
| Licenses | $12.4M | 37.5% |
| Assay and other service revenue | $2.0M | 6.0% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $21.1M | 63.8% |
| Outside the United States | $11.9M | 36.2% |
Company events
The newest 8-K filings of 53 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 14 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 16 Jun 2026 | 8-K | Delisting notice | 3.01 |
| 12 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 27 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 24 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 20 Mar 2026 | 8-K | Delisting notice | 3.01 |
| 12 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 12 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 5 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 22 Sep 2025 | 8-K | Restructuring, Investor update | 2.05, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 116 held.
| Filed | Form | Period |
|---|---|---|
| 14 Oct 2026 | 8-K | 14 Oct 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 17 Jun 2026 | 8-K | 17 Jun 2026 |
| 16 Jun 2026 | 8-K | 10 Jun 2026 |
| 13 May 2026 | 10-Q | 31 Mar 2026 |
| 12 May 2026 | 8-K | 12 May 2026 |
| 29 Apr 2026 | ARS | 31 Dec 2025 |
| 29 Apr 2026 | DEFA14A | – |
| 29 Apr 2026 | DEF 14A | 17 Jun 2026 |
| 15 Apr 2026 | S-8 | – |
| 27 Mar 2026 | 8-K | 23 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 17 Mar 2026 | Swirsky Douglas J, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 10,142 | $0.81 | $8.3K | 151,669 | 19 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 Oct 2026 | Liontrust Investment Partners LLP | 13D | 5% | 5.2M |
| 4 Aug 2026 | RIVER GLOBAL INVESTORS LLP | 13D | 0.8% | 834.1K |
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 1.3% | 1.4M |
| 14 May 2026 | RIVER GLOBAL INVESTORS LLP | 13D | 6.1% | 6.5M |
| 10 Apr 2026 | Mirabella Financial Services LLP | 13G amended | 0% | 0 |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Cadian Capital Management, LP | 13G amended | 3.5% | 3.7M |
| 5 Feb 2026 | Capricorn Fund Managers Ltd | 13G | 7.7% | 8.2M |
| 21 Jan 2026 | BlackRock, Inc. | 13G amended | 6.6% | 7.0M |
| 14 Nov 2025 | Cadian Capital Management, LP | 13G amended | 7.7% | 8.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.8M | +68.06% | 1.07 |
| 30 Sep 2026 | 1.1M | -6.87% | 3.14 |
| 15 Sep 2026 | 1.2M | -10.09% | 2.81 |
| 31 Aug 2026 | 1.3M | +6.2% | 2.37 |
| 14 Aug 2026 | 1.2M | -1.36% | 1.13 |
| 31 Jul 2026 | 1.2M | -11.65% | 1.58 |
| 15 Jul 2026 | 1.4M | -7.2% | 1.22 |
| 30 Jun 2026 | 1.5M | -64.25% | 1 |
Funds that hold it
From each fund's latest Form 13F.
155 funds held it at 30 Jun 2026: 76 added and 28 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | $10.1M | 0 |
| Vitruvian Partners LLP | 5,043,356 | $6.2M | 0 |
| Vanguard Capital Management LLC | 4,031,284 | $5.0M | +49,468 |
| Morgan Stanley | 3,694,049 | $4.5M | +5,918 |
| Mudita Advisors LLP | 3,370,689 | $4.1M | 0 |
| BlackRock, Inc. | 3,060,960 | $3.8M | -5,737,513 |
| Brooklands Fund Management Ltd | 2,848,083 | $3.7M | +658,063 |
| BNP Paribas Asset Management Holding S.A. | 2,773,554 | $3.4M | 0 |
| Cadian Capital Management, LP | 2,201,166 | $2.7M | +478,224 |
| Peapod Lane Capital LLC | 2,125,752 | $2.6M | +793,559 |
Peers
Companies in the same industry.
- IQVIA Holdings Inc. (IQV): revenue $17.3B, market value $44.1B
- Incyte Corp. (INCY): revenue $6.0B, market value $24.6B
- Medpace Holdings, Inc. (MEDP): revenue $2.8B, market value $18.2B
- Charles River Laboratories International, Inc. (CRL): revenue $4.0B, market value $17.2B
- ICON plc (ICLR): revenue $8.3B, market value $16.2B
- Absci Corp. (ABSI): revenue $1.6M, market value $1.9B
- OmniAb, Inc. (OABI): revenue $40.2M, market value $744.6M
- NRC Health (NRC): revenue $140.0M, market value $526.5M